|

QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy

RECRUITINGSponsored by Odense University Hospital
Actively Recruiting
SponsorOdense University Hospital
Started2026-03-18
Est. completion2027-10-01
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The goal of this observational study is to see how type 2 diabetes affects quality of life in cancer patients receiving immunotherapy. We want to know if patients with diabetes have a greater decline in quality of life over six months compared to those without. The main question we aim to answer is: \- How does quality of life change over six months in patients with versus without diabetes? Participants will complete quality-of-life surveys at the start, then at 3 and 6 months. This will help us see if diabetes adds extra challenges during cancer treatment

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥18 years.
* Histologically confirmed solid malignant tumor.
* Planned treatment with ICI monotherapy or dual-ICI combination therapy (metastatic, adjuvant, or neo-adjuvant settings).
* Previous systemic anticancer therapy other than ICI is allowed.
* Ability and willingness to provide written informed consent and to complete HRQoL questionnaires.
* Sufficient Danish language proficiency to read, and complete study questionnaires.

Exclusion Criteria:

* Previous ICI treatment within 6 months.
* Concurrent systemic anticancer therapy other than ICI.
* Declines or does not provide informed consent.
* Cognitive or physical impairment preventing valid consent or completion of patient-reported outcomes.

Conditions3

CancerDiabetesType 2 Diabetes

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.